Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Axel Hauschild et al.|New England Journal of Medicine|2017Cited by 1.5k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Anne-Marie Martin et al.|The Lancet Oncology|2012Cited by 906
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Aleksandar Sekulić, Michael R. Migden et al.|BMC Cancer|2017Cited by 412
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, Axel Hauschild et al.|New England Journal of Medicine|2020Cited by 406